Complete Genomics Inks Deal with Investment Bank for Potential Share Sale | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Complete Genomics today announced an agreement with investment bank MLV & Co. for the potential sale of an aggregate of $30 million of its common stock.

The sale of Complete Genomics' stock would be made on the Nasdaq Global Market under the Mountain View, Calif.-based firm's currently effective Form S-3 at market prices. Shares also may be sold through MLV at negotiated prices or at prices related to the prevailing market price, Complete Genomics said.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The Wall Street Journal reports that National Institutes of Health Director Francis Collins' response to contamination concerns at the agency might have delayed care.

The final revision of the Common Rule doesn't include the proposed change requiring consent for leftover biospecimens.

The first Reproducibility Project: Cancer Biology papers show mixed results.

In Nature this week: mobile phone-based targeted DNA sequencing, and more.